Investigational Drug Information for Laninamivir

What is the development status for investigational drug Laninamivir?

Laninamivir is an investigational drug.

There have been 5 clinical trials for Laninamivir. The most recent clinical trial was a Phase 2 trial, which was initiated on December 22^nd 2022.

The most common disease conditions in clinical trials are Influenza, Human, Asthma, and [disabled in preview]. The leading clinical trial sponsors are Biota Scientific Management Pty Ltd, Department of Health and Human Services, and University of Oxford.

Summary for Laninamivir

US Patents	0
International Patents	0
US Patent Applications	453
WIPO Patent Applications	166
Japanese Patent Applications	135
Clinical Trial Progress	Phase 2 (2022-12-22)
Vendors	45

Recent Clinical Trials for Laninamivir

Title	Sponsor	Phase
ADaptive ASsessment of TReatments for influenzA: A Phase 2 Platform Trial of Antiviral Pharmacodynamics in Early Symptomatic Influenza	University of Oxford	Phase 2
Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza	Department of Health and Human Services	Phase 1/Phase 2
Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza	Biota Scientific Management Pty Ltd	Phase 1/Phase 2

See all Laninamivir clinical trials

Clinical Trial Summary for Laninamivir

Top disease conditions for Laninamivir

Top clinical trial sponsors for Laninamivir

See all Laninamivir clinical trials

US Patents for Laninamivir

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Laninamivir Development Update, Patent Position, FDA Status, and Market Projection

Last updated: September 3, 2026

Laninamivir is a long-acting inhaled neuraminidase inhibitor marketed in Japan as Inavir by Daiichi Sankyo. Its main product is laninamivir octanoate, a prodrug converted in the respiratory tract to laninamivir. Japan approved Inavir for influenza A and B treatment in 2010 and prophylaxis in 2011. Development outside Japan has not produced broad regulatory commercialization, and no U.S. or European approval has been established.

The commercial outlook is therefore concentrated in Japan and depends on seasonal influenza incidence, public-health procurement, physician adoption, and competition from oseltamivir, zanamivir, peramivir, and newer agents such as baloxavir marboxil.

What is the current development status of laninamivir?

Laninamivir is commercially available in Japan but remains an internationally limited influenza product.

Development timeline

Year	Development or regulatory event
2000s	Daiichi Sankyo develops laninamivir octanoate as a long-acting inhaled neuraminidase inhibitor
2009	Clinical development accelerates during the H1N1 influenza pandemic period
2010	Japanese approval for treatment of influenza A and B
2011	Japanese approval expanded to prophylaxis
2011-2015	International development and partnering activity, including work with Biota Pharmaceuticals
2014-2016	Overseas clinical development does not produce a major global launch
2020-2022	COVID-19 reduces routine influenza circulation and influenza antiviral demand
2022 onward	Japan remains the principal commercial market; no broad international regulatory expansion is evident in public product information

Laninamivir’s distinguishing property is prolonged antiviral activity after a single inhaled dose. The approved treatment regimen is generally one administration for adults and adolescents, with dosing differentiated by age and body weight. That profile contrasts with oseltamivir, which is normally administered twice daily for five days.

The product is used for uncomplicated influenza rather than as a treatment for severe hospitalized disease. Its clinical value is highest where adherence to a multi-day oral regimen is difficult or where rapid completion of therapy is preferred.

What is the FDA and Orange Book status of laninamivir?

Laninamivir has no established U.S. FDA approval and no U.S. Orange Book listing.

Regulatory item	Status
FDA approval	None identified
U.S. New Drug Application	No publicly established approved application
Orange Book listing	None
European Medicines Agency approval	No broad marketing authorization established
Japanese approval	Yes
Japanese product	Inavir, laninamivir octanoate inhalation
Therapeutic category	Influenza A and B antiviral
FDA exclusivity	Not applicable without U.S. approval
U.S. generic competition	No approved generic market identified

The lack of an FDA approval removes the normal U.S. reference-product framework for an Abbreviated New Drug Application. A future U.S. entrant would likely need a full regulatory development strategy rather than rely on a conventional Orange Book-based Paragraph IV launch pathway.

What patents protect laninamivir and Inavir?

The patent estate is centered on the laninamivir active compound, the octanoate prodrug, inhaled formulations, and manufacturing processes. Daiichi Sankyo is the principal originator associated with the product.

Publicly available product and regulatory materials do not establish a single current patent expiration date that controls global commercial entry. Patent term varies by jurisdiction, patent family, prosecution history, supplementary protection rights, and whether claims cover the active compound, prodrug, formulation, or use.

Core patent categories

Patent category	Commercial relevance
Laninamivir compound claims	Protect the active neuraminidase inhibitor
Laninamivir octanoate prodrug claims	Protect the inhaled long-acting form used in Inavir
Inhalation formulation claims	Cover dry-powder or device-compatible delivery systems
Method-of-treatment claims	Cover treatment or prevention of influenza A and B
Manufacturing claims	Protect synthesis, intermediates, purification, and formulation processes
Combination or regimen claims	May address single-dose administration or prophylactic use

The strongest historical protection was likely associated with the composition and prodrug claims. As those claims age, residual protection depends increasingly on formulation, delivery-device, manufacturing, and method-of-use patents.

How strong is the laninamivir patent estate?

The estate is commercially meaningful in Japan but less valuable globally than the estates supporting major U.S.-market influenza products.

Its strengths are:

• A differentiated long-acting inhaled prodrug.
• A single-administration treatment regimen.
• Originator control over Japanese commercialization.
• Potential formulation and device barriers beyond the base compound.

Its weaknesses are:

• No established U.S. or European product franchise.
• Limited global sales infrastructure.
• A mature neuraminidase-inhibitor mechanism.
• Substitution from oral antivirals and newer single-dose products.
• Lower commercial incentives for a complex inhaled generic compared with oral oseltamivir.

The practical entry barrier is therefore a combination of remaining patent rights, inhalation-device development, bioequivalence or comparative clinical requirements, manufacturing know-how, and limited market scale.

When does laninamivir lose exclusivity?

No single worldwide loss-of-exclusivity date applies to laninamivir.

Japan approved Inavir in 2010. Japanese pharmaceutical re-examination protection for a new active pharmaceutical product commonly extends beyond the initial approval period, but that regulatory protection is separate from patent expiration. Patent terms must be assessed by family and jurisdiction.

A useful commercial timeline is:

Period	Exclusivity assessment
2010-2018	Core Japanese regulatory protection and active originator exclusivity
2019-2024	Mature branded product period; patent and formulation rights become more important
2025-2030	Increasing exposure to patent expiry, process development, and potential local generic competition
After 2030	Commercial protection depends mainly on surviving formulation, device, use, and manufacturing rights

This is a market-planning range, not a single legal expiration date. A company evaluating entry must map Japanese patent families, expiration dates, terminal disclaimers, patent-term adjustments, and any pediatric or supplementary protection provisions.

Are there Paragraph IV challenges to laninamivir?

No material U.S. Paragraph IV litigation involving laninamivir has become an established market event because laninamivir is not an FDA-approved Orange Book-listed product.

Japan may support challenges based on patent invalidity, non-infringement, or generic approval timing, but Japanese patent disputes do not use the U.S. Paragraph IV framework. Publicly visible global litigation has not established a major patent challenge comparable with disputes involving oseltamivir, baloxavir, or high-revenue specialty drugs.

The most credible future challenge would likely involve:

1. A Japanese generic or authorized generic manufacturer.
2. A dry-powder inhalation product using laninamivir octanoate.
3. A process claim or formulation challenge after core compound protection weakens.
4. A declaration that the proposed product does not infringe remaining method-of-use claims.

What formulations are protected by laninamivir patents?

Inavir is an inhaled dry-powder formulation containing laninamivir octanoate. The formulation is designed to deliver the prodrug to the respiratory tract, where it is converted to active laninamivir.

Relevant formulation and delivery barriers include:

• Particle-size distribution.
• Powder flow and dispersion properties.
• Device metering and dose uniformity.
• Stability during storage.
• Conversion of the prodrug to active laninamivir.
• Local respiratory deposition.
• Single-dose administration.
• Pediatric usability.

An oral laninamivir product would not be a direct substitute from a patent or regulatory perspective. It would require a separate formulation, pharmacokinetic profile, and clinical or bridging strategy.

The inhalation device may also create a practical barrier even where patent protection is weak. A generic manufacturer must reproduce drug delivery performance, not only the active pharmaceutical ingredient.

What clinical advantages and limitations does laninamivir have?

Laninamivir’s main clinical advantage is the single-dose regimen. The principal limitation is the inhaled route.

Attribute	Laninamivir	Oseltamivir	Zanamivir	Baloxavir
Route	Inhaled	Oral	Inhaled	Oral
Typical treatment schedule	Single administration	Twice daily for five days	Twice daily for five days	Single oral dose
Mechanism	Neuraminidase inhibition	Neuraminidase inhibition	Neuraminidase inhibition	Cap-dependent endonuclease inhibition
Main commercial market	Japan	Global	Global but smaller	Japan and selected global markets
Key limitation	Inhalation technique and device dependence	Multi-day adherence	Bronchospasm and inhalation limitations	Resistance concerns and price
Generic substitution risk	Moderate in Japan	High in many markets	Moderate	Emerging

Clinical trials generally positioned laninamivir as comparable to existing neuraminidase inhibitors for uncomplicated influenza, with adherence convenience as the main differentiator. The product does not eliminate the need for early treatment, accurate diagnosis, or appropriate patient selection.

How does laninamivir compare with competing influenza antivirals?

Laninamivir versus oseltamivir

Oseltamivir has the stronger global market position, wider regulatory footprint, oral administration, and extensive public-health stockpiling history. Laninamivir has a simpler dosing schedule but relies on inhalation.

Oseltamivir is more exposed to conventional oral generic competition. Laninamivir is harder to copy technically because the entrant must develop both the prodrug and a reliable inhalation delivery system.

Laninamivir versus baloxavir

Baloxavir is the closest commercial competitor on dosing convenience because it is administered as a single oral dose. Its oral route gives it an important advantage in children, older adults, and patients unable to use an inhaler.

Laninamivir retains a potential role where inhaled delivery is acceptable and where Japanese prescribers value established use and local availability.

Laninamivir versus peramivir

Peramivir is administered intravenously and is more relevant to patients who cannot take oral or inhaled therapy. It is less convenient for routine outpatient treatment but can occupy a hospital-oriented segment.

What licensing deals affected laninamivir development?

Daiichi Sankyo has been the central originator and Japanese commercial company. Biota Pharmaceuticals was involved in international development and commercialization efforts for laninamivir outside Japan under a licensing arrangement with Daiichi Sankyo.

The international program did not create a major global product. Biota’s later corporate and financial difficulties, followed by its acquisition by Vectura Group, reduced the likelihood of a large independent international laninamivir franchise. The commercial rights and development history should therefore be analyzed separately by territory rather than treated as a single global license.

No major current licensing transaction has established laninamivir as a platform asset comparable with leading respiratory antiviral programs.

What litigation and settlement agreements affect laninamivir?

No major public settlement has reshaped the global laninamivir market. No established U.S. patent litigation or Paragraph IV settlement controls launch timing.

The principal legal risks are expected to be jurisdiction-specific:

• Japanese patent invalidity or non-infringement actions.
• Disputes over inhaler-device claims.
• Process-patent challenges.
• Regulatory disputes over generic equivalence.
• Trademark or distribution disputes involving Inavir.

The absence of high-profile litigation reduces legal uncertainty but also indicates that the product has not generated the sales exposure that typically attracts aggressive multinational generic litigation.

What generic entry risks exist for Inavir?

Generic entry risk is moderate in Japan and low in the United States and Europe because there is no established approved product in those markets.

Japan

The most plausible Japanese entrant would need to address:

• Laninamivir octanoate API manufacture.
• Dry-powder formulation.
• Inhaler-device compatibility.
• Dose uniformity.
• Product stability.
• Japanese regulatory requirements for therapeutic equivalence.
• Remaining composition, formulation, process, and use patents.

An authorized generic could enter earlier or with lower technical risk than an independent generic, but no major authorized-generic launch has been established publicly.

United States and Europe

An entrant would face a larger development and commercial problem. It would need to create regulatory value in markets where physicians already have access to oral oseltamivir, baloxavir, inhaled zanamivir, or intravenous peramivir. The cost of inhalation-device development would be difficult to justify without a differentiated indication or public-health procurement contract.

What is the market size and revenue exposure for laninamivir?

Daiichi Sankyo does not report Inavir as a major standalone global revenue category in the manner used for its leading oncology and cardiovascular products. Publicly available company reporting does not provide a consistently reported annual worldwide Inavir revenue figure.

The addressable commercial market can be modeled through Japanese influenza treatment volume rather than global prevalence.

Base-case market projection

Scenario	2025-2027 annual Japanese product sales	2028-2030 annual sales	Main assumptions
Bear case	¥5 billion-¥10 billion	¥3 billion-¥7 billion	Mild influenza seasons, price pressure, greater baloxavir use
Base case	¥10 billion-¥20 billion	¥8 billion-¥15 billion	Recurring seasonal demand and continued Japanese prescribing
Bull case	¥20 billion-¥35 billion	¥15 billion-¥25 billion	Severe influenza seasons, institutional procurement, limited generic erosion

These figures are scenario estimates rather than reported company guidance. They represent product-level Japanese sales potential, not Daiichi Sankyo consolidated revenue.

The key variables are:

• Influenza incidence and timing.
• Pediatric prescribing.
• Relative use of baloxavir and oseltamivir.
• Japanese drug-price revisions.
• Generic or authorized-generic entry.
• Public-health stockpiling.
• Resistance patterns.
• Product availability during seasonal surges.

Laninamivir has limited exposure to the large global influenza market because international approvals and distribution remain constrained. Its revenue profile is more seasonal and geographically concentrated than that of oseltamivir.

What is the competitive outlook for laninamivir?

Laninamivir’s competitive position is stable but narrow.

The product has a durable niche in Japan because it offers single-dose inhaled treatment and has established physician familiarity. Its market share is vulnerable to baloxavir, which provides single-dose oral administration, and to oseltamivir, which has broad availability and lower-cost generic supply.

The product could regain strategic relevance if:

• Influenza seasons produce high outpatient volumes.
• Resistance reduces confidence in existing therapies.
• Combination therapy or prophylaxis studies show incremental benefit.
• The company develops a more usable inhalation device.
• Government procurement values stockpile stability and single-dose administration.
• New formulations expand use in children or patients who cannot use current devices.

No major late-stage pipeline expansion is publicly established. The likely value proposition is lifecycle management of an existing Japanese product rather than a new global launch.

Is laninamivir a biologic or a biosimilar risk?

Laninamivir is a chemically synthesized small-molecule antiviral, not a biologic. Biosimilar competition is not relevant.

The relevant competition is from:

• Small-molecule generics.
• Authorized generics.
• Alternative neuraminidase inhibitors.
• Oral endonuclease inhibitors.
• New influenza antivirals under development.
• Non-pharmaceutical prevention and vaccination programs.

Generic development is more complex than for an ordinary tablet because the product combines a prodrug, inhaled powder, and device performance.

Key Takeaways

• Laninamivir is an established Japanese influenza antiviral marketed as Inavir by Daiichi Sankyo.
• Its principal differentiation is single-dose inhaled delivery.
• Japan is the dominant commercial market; no broad U.S. or European approval is established.
• Laninamivir has no meaningful FDA Orange Book or Paragraph IV litigation pathway.
• Patent value is concentrated in compound, octanoate prodrug, formulation, inhalation-device, method-of-use, and manufacturing claims.
• The relevant loss-of-exclusivity window is jurisdiction-specific, with increasing generic exposure likely during 2025-2030.
• Biosimilar risk does not apply because laninamivir is a small molecule.
• Baloxavir is the strongest direct commercial competitor on dosing convenience.
• Base-case Japanese product sales are estimated at ¥10 billion-¥20 billion annually through 2027, declining toward ¥8 billion-¥15 billion during 2028-2030 if price and generic pressure increase.
• Laninamivir is more likely to remain a profitable regional influenza franchise than become a global blockbuster.

Frequently Asked Questions

Is laninamivir approved in the United States?

No FDA-approved laninamivir product has been established, and the drug has no conventional U.S. Orange Book listing.

What company manufactures Inavir?

Daiichi Sankyo developed and markets Inavir, the Japanese brand containing laninamivir octanoate.

Is laninamivir effective against influenza B?

Yes. Inavir is approved in Japan for treatment of influenza A and B, subject to applicable prescribing information and clinical use requirements.

Can laninamivir replace oseltamivir?

No. Laninamivir provides a single-dose inhaled alternative, while oseltamivir has oral dosing, broader international availability, and a larger public-health distribution base.

Will laninamivir become a global influenza blockbuster?

That outcome is unlikely without new international approvals, expanded licensing, or a materially differentiated formulation. The current commercial case is primarily Japan-focused.

References

1. Daiichi Sankyo Co., Ltd. (2024). Annual report 2024. Daiichi Sankyo.

2. Daiichi Sankyo Co., Ltd. (2024). Inavir package insert and product information. Daiichi Sankyo.

3. Biota Pharmaceuticals, Inc. (2012). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

4. Vectura Group plc. (2016). Annual report and accounts 2016. Vectura Group.

5. World Health Organization. (2021). Antiviral agents for the treatment and post-exposure prophylaxis of influenza. World Health Organization.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

7. National Institute of Infectious Diseases, Japan. (2024). Influenza surveillance and antiviral use information. Ministry of Health, Labour and Welfare, Japan.